Comparative Cardiovascular Risk of Semaglutide in Cancer Survivors | Retatrutide News

The study evaluates cardiovascular risks of semaglutide versus other GLP-1 agonists in cancer survivors. This research may impact future GLP-1 drug deve...
Clinical Trials · October 30, 2026